Výsledky vyhledávání - "Viktor GrÃ¼nwald"

Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL

Autor: Christian Doehn, Viktor GrÃ¼nwald, Jens Bedke, Jan Schleicher, P. J. Goebell, Tanja Medinger, Dunja Klein, Martin Boegemann, Thomas Steiner, Rainer Ehness, Alexander Petzold, Martin Schostak, Thomas Wolf, Christiane Hering-Schubert, Carsten Grüllich, Manfred Welslau

Publikováno v: Journal of Clinical Oncology. 36:4584-4584

4584Background: The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has evolved rapidly with the approval of targeted therapies like tyrosine kinase-, mTOR-, multikinase-, and immu...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a78bc327a84c15891433a31290c46a81
https://doi.org/10.1200/jco.2018.36.15_suppl.4584

Zobrazit plný text záznamu

Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment

Autor: Arnold Ganser, Hendrik Eggers, Philipp Ivanyi, Viktor GrÃ¼nwald, Christoph W. M. Reuter, Maria-Luisa Tiemann

Publikováno v: Journal of Clinical Oncology. 36:4581-4581

4581Background: ASDT is applicable to a fraction of mRCC patients (pts). We investigated clinical outcome of ASDT and report on efficacy of medical treatment (Rx). Methods: Between 4/2000-3/2016 pa...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfab4dbab9421bd6f4e83457654219ff
https://doi.org/10.1200/jco.2018.36.15_suppl.4581

Zobrazit plný text záznamu

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial

Autor: Viktor GrÃ¼nwald, Justin Doan, Sabeen Mekan, Bernard Escudier, Cristina Ivanescu, Hans J. Hammers, Robert J. Motzer, Saby George, Jean Paty, Marc-Oliver Grimm, David Cella, Brian I. Rini, Paul C. Nathan

Publikováno v: Journal of Clinical Oncology. 36:3073-3073

3073Background: In CheckMate 214, overall survival (OS) with nivolumab + ipilimumab (N+I) was superior to sunitinib (S; HR, 0.63; P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec847d0742682a34951df85ac7c7453f
https://doi.org/10.1200/jco.2018.36.15_suppl.3073

Zobrazit plný text záznamu

Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastastic soft tissue sarcoma (a/m STS)

Autor: Patrick Zardo, Christoph W. M. Reuter, Philipp Ivanyi, Hans Christiansen, Hendik Eggers, Arnold Ganser, Martin Panzica, Florain Länger, Katharina Stange, Viktor GrÃ¼nwald

Publikováno v: Journal of Clinical Oncology. 36:e23566-e23566

e23566Background: MT applies to a selected group of pts with a/m STS. The impact of MT on prognosis remains undefined. We report results on palliative medical treatment (Rx) with MT(+) or without M...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b451f9a3bc97dc8778254f1127a84df
https://doi.org/10.1200/jco.2018.36.15_suppl.e23566

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání